See more : B&C Speakers S.p.A. (BEC.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Quotient Limited (QTNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quotient Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- Human Creation Holdings, Inc. (7361.T) Income Statement Analysis – Financial Results
- Investors Title Company (ITIC) Income Statement Analysis – Financial Results
- TCL Electronics Holdings Limited (TCLHF) Income Statement Analysis – Financial Results
- PwrCor, Inc. (PWCO) Income Statement Analysis – Financial Results
- Zegna (IIAC-UN) Income Statement Analysis – Financial Results
Quotient Limited (QTNT)
About Quotient Limited
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.51M | 43.38M | 32.66M | 29.13M | 24.73M | 22.23M | 18.52M | 18.41M | 19.76M | 14.37M | 12.22M | 10.03M |
| Cost of Revenue | 23.57M | 20.07M | 17.80M | 17.23M | 10.47M | 10.84M | 9.66M | 9.76M | 8.41M | 7.17M | 6.75M | 5.63M |
| Gross Profit | 14.95M | 23.31M | 14.86M | 11.90M | 14.26M | 11.38M | 8.86M | 8.65M | 11.35M | 7.20M | 5.47M | 4.41M |
| Gross Profit Ratio | 38.80% | 53.72% | 45.49% | 40.86% | 57.66% | 51.21% | 47.86% | 46.96% | 57.45% | 50.11% | 44.77% | 43.91% |
| Research & Development | 58.69M | 54.17M | 53.74M | 50.68M | 51.20M | 57.06M | 28.78M | 19.22M | 8.07M | 2.62M | 1.75M | 1.70M |
| General & Administrative | 49.06M | 41.80M | 31.95M | 31.55M | 25.70M | 22.72M | 26.10M | 16.39M | 9.47M | 6.82M | 6.01M | 5.35M |
| Selling & Marketing | 11.02M | 9.85M | 9.85M | 8.64M | 7.35M | 5.66M | 3.07M | 2.75M | 2.71M | 2.25M | 1.67M | 1.46M |
| SG&A | 60.08M | 51.65M | 41.80M | 40.18M | 33.05M | 28.38M | 29.17M | 19.14M | 12.18M | 9.08M | 7.69M | 6.80M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 118.77M | 105.81M | 95.55M | 90.86M | 84.25M | 85.44M | 57.95M | 38.36M | 20.24M | 11.69M | 9.43M | 8.51M |
| Cost & Expenses | 142.34M | 125.89M | 113.35M | 108.09M | 94.72M | 96.29M | 67.61M | 48.12M | 28.65M | 18.86M | 16.18M | 14.13M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 57.00K | 87.00K | 0.00 |
| Interest Expense | 31.95M | 25.92M | 23.86M | 20.02M | 15.37M | 9.90M | 4.15M | 2.32M | 1.08M | 291.00K | 427.00K | 312.00K |
| Depreciation & Amortization | 7.42M | 8.62M | 12.28M | 12.77M | 10.41M | 9.46M | 2.95M | 1.68M | 622.00K | 691.00K | 989.00K | 980.00K |
| EBITDA | -84.80M | -72.01M | -65.98M | -72.56M | -57.22M | -65.71M | -26.78M | -55.07M | -8.47M | -3.73M | -3.06M | -3.33M |
| EBITDA Ratio | -220.17% | -165.99% | -202.04% | -249.05% | -231.35% | -295.61% | -144.60% | -299.15% | -42.86% | -25.97% | -25.02% | -33.18% |
| Operating Income | -92.22M | -82.51M | -80.69M | -78.96M | -69.99M | -74.06M | -49.09M | -29.71M | -8.89M | -4.49M | -3.96M | -4.10M |
| Operating Income Ratio | -239.43% | -190.20% | -247.09% | -271.01% | -282.99% | -333.19% | -265.03% | -161.42% | -45.01% | -31.25% | -32.44% | -40.85% |
| Total Other Income/Expenses | -31.95M | -24.04M | -21.42M | -26.39M | -13.00M | -11.01M | 15.21M | -29.35M | -1.27M | -223.00K | -509.00K | -522.00K |
| Income Before Tax | -124.17M | -106.54M | -102.11M | -105.34M | -82.99M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Income Before Tax Ratio | -322.40% | -245.61% | -312.69% | -361.58% | -335.55% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| Income Tax Expense | 961.00K | 1.93M | 661.00K | 44.00K | -649.00K | -1.11M | 19.36M | -27.03M | -197.00K | 68.00K | -82.00K | -210.00K |
| Net Income | -125.13M | -108.47M | -102.77M | -105.39M | -82.34M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Net Income Ratio | -324.89% | -250.05% | -314.71% | -361.73% | -332.92% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| EPS | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| EPS Diluted | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| Weighted Avg Shares Out | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
| Weighted Avg Shares Out (Dil) | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
Quotient Earnings Preview
Will Quotient (QTNT) Report Negative Earnings Next Week? What You Should Know
Quotient Limited Wins 2021 BIG Innovation Award
Quotient Limited Announces Departure of Chief Operating Officer
Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market
Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data
Quotient Limited (QTNT) CEO Franz Walt on Q2 2021 Results - Earnings Call Transcript
Quotient Limited Reports Second Quarter Fiscal 2021 Results and Business Update
Source: https://incomestatements.info
Category: Stock Reports